SAVA NASDAQ
Cassava Sciences, Inc.
1W: -11.3%
1M: -4.4%
3M: -38.8%
YTD: -6.2%
1Y: -26.6%
3Y: -47.9%
5Y: -69.1%
$1.32
Last traded 2026-03-16 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$63.8M
52W Range1.15-4.98
Volume134,262
Avg Volume375,808
Beta-0.84
Dividend—
Analyst Ratings
Company Info
CEORichard Jon Barry
Employees30
SectorHealthcare
IndustryBiotechnology
IPO Date2000-07-14
Websitefilanatx.com
7801 North Capital of Texas Highway
Austin, TX 78731
US
Austin, TX 78731
US
512 501 2444
About Cassava Sciences, Inc.
Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders. The company's primary experimental drug, simufilam, a small-molecule compound, has successfully concluded its Phase 2b clinical trials. In parallel, they are advancing SavaDx, an investigational blood-based biomarker test designed to aid in the detection of Alzheimer's disease. Established in 1998 and headquartered in Austin, Texas, the company underwent a name change in March 2019, previously operating as Pain Therapeutics, Inc.
Latest News
Cassava Sciences (NASDAQ:FLNA) CEO Richard Barry Acquires 100,000 Shares of Stock
Cassava Sciences (NASDAQ:FLNA) CEO Richard Barry Buys 206,813 Shares of Stock
Cassava Sciences to rebrand to Filana Therapeutics
HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Cassava Announces Agreement to Settle Securities Class Action Litigation
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Anderson Robert Euge | P-Purchase | 8,600 | $2.90 | 2025-11-24 |
| Barry Richard | P-Purchase | 150,000 | $2.76 | 2025-11-20 |
| Barry Richard | P-Purchase | 73,385 | $2.75 | 2025-11-19 |
| Bir Dawn Carter | A-Award | 53,000 | $3.98 | 2025-10-21 |
| Bir Dawn Carter | 0 | — | 2025-10-21 |